Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $91.84 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average price of $91.75 and a 200-day moving average price of $83.97. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market capitalization of $114.46 billion, a PE ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently made changes to their positions in the company. FCG Investment Co lifted its stake in shares of Gilead Sciences by 9.8% in the 4th quarter. FCG Investment Co now owns 11,240 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 1,003 shares during the period. Lifestyle Asset Management Inc. bought a new position in Gilead Sciences in the fourth quarter worth approximately $228,000. Veracity Capital LLC boosted its stake in shares of Gilead Sciences by 58.2% during the 4th quarter. Veracity Capital LLC now owns 8,733 shares of the biopharmaceutical company’s stock worth $807,000 after acquiring an additional 3,213 shares during the last quarter. Donoghue Forlines LLC grew its position in shares of Gilead Sciences by 51.2% during the 4th quarter. Donoghue Forlines LLC now owns 39,954 shares of the biopharmaceutical company’s stock valued at $3,691,000 after acquiring an additional 13,524 shares during the period. Finally, Goldstein Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $218,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Barclays upped their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.